Opinion|Videos|January 17, 2025
Overview and Benefits of Port Delivery System with Ranibizumab
Panelists discuss how the port delivery system (PDS) with ranibizumab represents a paradigm shift in neovascular AMD treatment by utilizing a surgically implanted refillable device that provides continuous medication delivery for 6 months, offering patients a preferred alternative to frequent intravitreal injections while ensuring consistent therapeutic levels.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Can you provide an overview of the port delivery device with ranibizumab approved for treating neovascular AMD?
- How does the device function?
- What are the benefits of using the port delivery device with ranibizumab?
- Certainty of 6 months of continuous anti-VEGF delivery
- Patients in clinical trials prefer PDS over intravitreal injections
Advertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.
Andrew G. Lee, MD, and Drew Carey, MD, discuss findings from a retrospective study examining ischemic stroke risk in patients with non-arteritic anterior ischemic optic neuropathy and the implications for vascular risk factor management.
Length and width, not thickness, emerge as key drivers of higher-order aberrations.
What the approval of a second targeted biologic means for patients, practice, and the evolving TED treatment landscape
Three real-world cases illustrate strategies to identify and manage GA across a range of scenarios, from coexisting wet age-related macular degeneration to functionally monocular patients.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
AAO 2026: Tinlarebant in Stargardt disease: Jacque Duncan, MD, on DRAGON results
2
AAO 2026: MCO-010 sustains vision gains in RP through 4 years
3
AAO 2026: What the first whole eye transplant has taught surgeons
4
AAO 2026: What the evidence really shows about nutrition and the eye
5